CTOs on the Move

Inspire Medical Systems

www.inspiresleep.com

 
Inspire Medical Systems, Inc. has developed the world`s first fully implanted neurostimulation device approved by the FDA for the treatment of Obstructive Sleep Apnea (OSA). The Inspire system uses well-established neurostimulation technologies and incorporates a proprietary algorithm that stimulates key airway muscles based on a patient`s unique breathing patterns. Inspire therapy is designed to reduce OSA severity and improve quality of life for patients living with this challenging condition. Inspire therapy works inside your body, and with your natural breathing process. It might be right for you if you have been diagnosed with OSA, and can`t use or don`t get ...
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.inspiresleep.com
  • 5500 Wayzata Boulevard Suite 1600
    Golden Valley, MN USA 55416
  • Phone: 844.672.4357

Executives

Name Title Contact Details

Funding

Inspire Medical Systems raised $38M on 11/18/2016
Inspire Medical Systems raised $75M on 12/18/2018

Similar Companies

Mental Health Corporation of Denver

Mental Health Corporation of Denver is a Denver, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bioseal Medical Packaging Concepts

Bioseal Medical Packaging Concepts is a Placentia, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Specialty Medical Supplies Inc

Specialty Medical Supplies Inc is a Pompano Beach, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AUSPICE

AUSPICE is a Waltham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Neurolens

Modern lifestyles and persistent near vision utilization cause a majority of patients to experience the reduced visual acuity and painful symptoms of eye misalignment – headaches, eye strain, neck and shoulder pain, motion sickness and dry eye sensation. Neurolens addresses common binocular vision issues using a three-step process. Step one is efficiently identifying patient symptomology using a basic online symptom screener that every patient can complete in minutes. This information goes directly to the Neurolens Measurement Device, Gen 2—or NMD2—ready for step two, which is accurately and objectively measuring the patient`s level of misalignment. The NMD2 is an objective, accurate and repeatable way to measure eye misalignment as small as 0.01 Prism Diopters. Most importantly, step three is correcting eye misalignment with a proven lens solution. Neurolenses address binocular vision issues by providing a contoured prism lens design that gradually delivers more prism in the lens corridor from distance to near. Neurolenses are proven to have a profound impact on a patient`s visual clarity and comfort. In fact, 93% of patients responded positively to wearing Neurolenses. Over 81% of patients suffering from chronic daily headaches reported their symptoms were substantially reduced or basically gone after wearing Neurolenses for 90 days. Neurolens—recognized in 2022 as one of the 30 fastest growing private companies in the healthcare industry by Inc. Magazine—is confident that appropriately addressing growing binocular vision issues will become a standard of care in this industry, unlocking dramatic patient outcomes and practice growth.